ClearPoint Neuro (CLPT) to Release Earnings on Tuesday

ClearPoint Neuro (NASDAQ:CLPT) is expected to release its Q2 2025 earnings data after the market closes on Tuesday, August 12th. Analysts expect ClearPoint Neuro to post earnings of ($0.20) per share and revenue of $9.20 million for the quarter. ClearPoint Neuro has set its FY 2025 guidance at EPS.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 64.51% and a negative return on equity of 78.09%. The firm had revenue of $8.49 million during the quarter, compared to analysts’ expectations of $8.21 million. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Price Performance

NASDAQ:CLPT opened at $10.82 on Friday. ClearPoint Neuro has a 1-year low of $8.64 and a 1-year high of $19.22. The firm’s fifty day moving average price is $11.58 and its 200 day moving average price is $13.27. The firm has a market cap of $302.85 million, a price-to-earnings ratio of -14.24 and a beta of 0.85.

Insider Transactions at ClearPoint Neuro

In related news, Director Timothy T. Richards sold 10,000 shares of the business’s stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $13.28, for a total transaction of $132,800.00. Following the completion of the transaction, the director owned 77,381 shares of the company’s stock, valued at approximately $1,027,619.68. The trade was a 11.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph Burnett sold 21,247 shares of the business’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $13.29, for a total value of $282,372.63. Following the transaction, the chief executive officer directly owned 243,522 shares of the company’s stock, valued at $3,236,407.38. This represents a 8.02% decrease in their position. The disclosure for this sale can be found here. Insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On ClearPoint Neuro

An institutional investor recently raised its position in ClearPoint Neuro stock. Goldman Sachs Group Inc. increased its stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 98.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 257,871 shares of the company’s stock after acquiring an additional 127,823 shares during the quarter. Goldman Sachs Group Inc. owned about 0.92% of ClearPoint Neuro worth $3,066,000 at the end of the most recent reporting period. 30.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wall Street Zen downgraded ClearPoint Neuro from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th. Stifel Nicolaus lifted their price target on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 1st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.